FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to substances and methods of treatment, prevention and improvement of the complement-related disease. There are offered various therapeutically effective aptamer/PEG conjugates. Aptamers under the present invention contain modified nucleotides that improves their resistance to enzymatic and chemical destruction, as well as to thermal and physical destruction. These aptamer/PEG conjugates are applicable as agent for therapy of the complement-related cardiac, inflammatory and autoimmune disorders, ischemia reperfusion injury and/or the other diseases or disorders wherein C5-mediated complement activation is involved.
EFFECT: development of the new agent and method of treatment, prevention and improvement of the complement-related disease.
20 cl, 67 dwg, 7 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPLEMENT-BINDING APTAMERS AND C5 AGENTS APPLICABLE FOR TREATING OCULAR DISORDERS | 2007 |
|
RU2477137C2 |
| NEW CONNECTING C5a NUCLEIC ACIDS | 2013 |
|
RU2645261C2 |
| METHODS AND COMPOSITIONS FOR TREATMENT OF DEGOS DISEASE | 2011 |
|
RU2570390C2 |
| HUMANIZED MODEL OF KIDNEY AND LIVER DISORDERS | 2018 |
|
RU2772583C2 |
| ANTI-C5a ANTIBODIES AND THEIR APPLICATIONS | 2018 |
|
RU2773779C2 |
| ORNITHODOROS MOUBATA AND COMPLEMENT INHIBITOR FOR TREATING COMPLEMENT-MEDIATED DISEASES OF PATIENT WITH COMPLEMENT C5 POLYMORPHISM | 2015 |
|
RU2700932C2 |
| ANTI-SENSE OLIGONUCLEOTIDES FOR TREATING ALLERGY AND PROLIFERATION OF NEOPLASTIC CELLS | 2005 |
|
RU2416412C2 |
| METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | 2012 |
|
RU2662563C2 |
| C5 ANTIBODY AND METHOD FOR PREVENTING AND TREATING COMPLEMENT-RELATED DISEASES | 2014 |
|
RU2663349C2 |
| MODULATION OF COMPLEMENT ACTIVITY | 2015 |
|
RU2670988C2 |
